HIV Breakthrough as New Injection 89% More Effective Than PrEP
"PrEP reduces the risk of getting HIV from sex by about 99 percent when taken as prescribed. Although there is less information about how effective PrEP pills are among people who inject drugs, we know that PrEP pills reduce the risk of getting HIV by at least 74 percent when taken as prescribed," the CDC says.
Twice-Yearly Injection 96% Effective in Preventing HIV Infection
People whose partners have HIV must remember to take antiretroviral pills every single day or risk infection themselves. But researchers have come up with a way to avoid that daily hassle – an injectable drug that patients would only have to receive twice a year.
THIS New Injection Is 96 Percent Effective In Protecting Against HIV With Just Two Doses A Year: Research
A new injectable drug, Sunlenca (lenacapavir), provides 96 per cent protection against HIV with just two doses annually, outperforming daily oral PrEP medications like Truvada. Clinical trials reveal its high efficacy and improved adherence,
Twice-Yearly Injection Reduces Risk of HIV Infection by 96%
For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including attending doctor's visits every three months and—most importantly—cons
New HIV prevention injection offers 96% protection
For oral medications that prevent new HIV infection to be effective, the patient must take certain actions, including attending doctor's visits every three months and – most importantly – consistency.
'Huge relief' as new drug found to effectively prevent HIV infection
A vaccination with the drug lenacapavir offers an effective protection against a HIV infection, according to newly published research from the pivotal phase-three study "Purpose 2". The option to vaccinate against HIV only every six months is a genuine breakthrough,
Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial
The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure prophylaxis (PrEP) against once-daily oral Truvada.
Gilead announces PURPOSE 2 trial data published in NEJM
Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal ...
EurekAlert!1d
Clinical trial at Emory University reveals twice-yearly injection to be 96% effective in HIV prevention
These daily oral antiretrovirals, more commonly referred to as PrEP (pre-exposure prophylaxis), such as Truvada®, are ...
HIV infections can be prevented – why some people act to protect themselves, and others don’t
People are at the heart of the HIV pandemic, so it’s important to understand how they make protection decisions.
Fewest New HIV Cases Since Late 1980s: UNAIDS Report
Fewer people contracted HIV last year than at any point since the rise of the disease in the late 1980s, the United Nations ...
Too Old to Operate1d
Q&A: Addressing Barriers to Long-Acting Injectable PrEP for Transgender Women
Research shows many transgender women in the U.S. express interest in long-acting injectable PrEP but face barriers to ...
How Gilead Is Driving Global Health Equity And Innovation
Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...
The Kenya Times on MSN1d
Bill Gates Opens Up on Finding Lifetime HIV Vaccine
U.S. philanthropist and entrepreneur Bill Gates has opened up about the search for a lifetime HIV vaccine, rather than one ...
Medscape3d
Family Doctors Can Intervene to Treat and Prevent STIs
Many family physicians may be unaware of doxy PEP as a means of avoiding STIs. “Doxy PEP is an incredible tool that can be ...